Therapeutic strategy for diabetic patients with cardiovascular-kidney-metabolic syndrome

Area of Science:

• Internal Medicine
• Cardiology
• Nephrology
• Endocrinology

Background:

• Cardiovascular-kidney-metabolic (CKM) syndrome is a multisystemic condition driven by interactions between cardiovascular disease, chronic kidney disease, and metabolic risk factors.
• This syndrome results in multiorgan dysfunction, significantly increasing the risk of cardiovascular events and adverse renal outcomes.
• CKM syndrome represents a substantial burden of morbidity and mortality globally.

Purpose of the Study:

• To review common antidiabetic agents with demonstrated cardiorenal benefits.
• To elaborate on the clinical efficacy of these agents in managing cardiovascular and kidney outcomes.
• To inform the development of a holistic CKM management framework and enhance clinical documentation skills.

Main Methods:

• Literature review of antidiabetic agents with cardiorenal benefits.
• Analysis of clinical trial data on efficacy in cardiovascular and kidney outcomes.
• Synthesis of findings to propose a CKM management framework.

Main Results:

• Several classes of antidiabetic drugs exhibit significant cardiorenal protective effects.
• These agents have shown efficacy in reducing cardiovascular events and slowing the progression of kidney disease.
• Individualized and precision medicine approaches are crucial for effective CKM management.

Conclusions:

• Antidiabetic drugs with cardiorenal benefits are pivotal in managing CKM syndrome.
• A comprehensive management strategy integrating pharmacotherapy and personalized approaches is essential.
• Further research and education are needed to optimize CKM care and clinical documentation.